| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Kaempferide does not have a single defined pharmacological target. It targets multiple pathways including Estrogen Receptor/ERR, Autophagy, Bacterial, Influenza Virus, Apoptosis, PI3K, Akt, GSK-3, FOXO, and β-catenin. As a phytoestrogen, it has been studied in the hypothalamic-pituitary-gonadal axis and various non-gonadal targets. Kaempferide triglycoside inhibits the proliferation of native and estrogen receptor overexpressing colon cancer cells via a mechanism not mediated by ligand binding-dependent estrogen receptor activation.
|
|---|---|
| ln Vitro |
In vitro, Kaempferide has anticancer, anti-inflammatory, antioxidant, antidiabetic, antiobesity, antihypertensive, and neuroprotective activities. It induces apoptosis and protects DNA from radiation-induced lesions. Kaempferide triglycoside inhibits the proliferation of native and estrogen receptor overexpressing colon cancer cells. Its diverse biological activities make it a valuable tool for studying various disease mechanisms.
|
| ln Vivo |
In vivo, Kaempferide has anticancer, anti-inflammatory, antioxidant, antidiabetic, antiobesity, antihypertensive, and neuroprotective activities. As a phytoestrogen, it has been studied for its effects on the hypothalamic-pituitary-gonadal axis. However, specific in vivo efficacy data from animal models is not detailed in the available sources. The compound's ability to protect DNA from radiation-induced lesions suggests potential applications in radioprotection.
|
| Enzyme Assay |
For flavonoid compounds, standard cell-free assays include antioxidant assays (DPPH, ABTS, FRAP), enzyme inhibition assays (e.g., PI3K, GSK-3), and receptor binding assays (e.g., estrogen receptor). These assays provide quantitative data on the compound's activity against various targets.
|
| Cell Assay |
For flavonoid compounds, standard cellular assays involve treatment of cancer cell lines or other cell types with the test compound for 24-72 hours. Cell viability (MTT or CellTiter-Glo), apoptosis (Annexin V/PI staining, caspase activity), and cell proliferation are assessed. Specific target modulation is assessed by western blot or reporter assays.
|
| Animal Protocol |
For in vivo evaluation of flavonoid compounds, standard animal models include tumor xenograft models, models of inflammation, diabetes, obesity, and hypertension. The compound is typically administered orally or intraperitoneally, and disease-specific endpoints are assessed.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Kaempferides have known human metabolites including kaempferol. Detailed pharmacokinetic data for Kaempferide is not provided in the available sources. The compound has a molecular weight of 300.26 and formula C₁₆H₁₂O₆. As a flavonoid with moderate lipophilicity, it would be expected to have reasonable oral absorption. Comprehensive PK studies would be required for therapeutic development. |
| Toxicity/Toxicokinetics |
Detailed toxicology data for Kaempferide is not provided in the available sources. As a naturally occurring flavonoid, it is likely to have a favorable safety profile at dietary levels. However, comprehensive toxicological evaluation would be required for therapeutic development. The compound is for research use only and not for therapeutic applications.
|
| References |
|
| Additional Infomation |
Kaempferide is a monomethoxyflavonoid, a 4'-O-methyl derivative of kaempferol. It possesses antihypertensive activity and is also a metabolite. It is a trihydroxyflavonoid, a monomethoxyflavonoid, and a 7-hydroxyflavonol. Its function is related to kaempferol. It is the conjugate acid of Kaempferide (1-). Kaempferide has been reported to exist in Araucaria heterophylla (Nothofagus nervosa), Phyllanthus virgatus, and several other organisms with relevant data.
Kaempferide is an O-methylated flavonol found in Kaempferia galanga. It has anticancer, anti-inflammatory, antioxidant, antidiabetic, antiobesity, antihypertensive, and neuroprotective activities. It targets multiple pathways including ER, PI3K, Akt, GSK-3, FOXO, and β-catenin. No regulatory approval has been identified. |
| Molecular Formula |
C16H12O6
|
|---|---|
| Molecular Weight |
300.2629
|
| Exact Mass |
300.063
|
| CAS # |
491-54-3
|
| PubChem CID |
5281666
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
543.8±50.0 °C at 760 mmHg
|
| Melting Point |
156-157ºC(lit.)
|
| Flash Point |
207.1±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.710
|
| LogP |
2.74
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
465
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SQFSKOYWJBQGKQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O6/c1-21-10-4-2-8(3-5-10)16-15(20)14(19)13-11(18)6-9(17)7-12(13)22-16/h2-7,17-18,20H,1H3
|
| Chemical Name |
3,5,7-trihydroxy-2-(4-methoxyphenyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~66.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (6.66 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3304 mL | 16.6522 mL | 33.3045 mL | |
| 5 mM | 0.6661 mL | 3.3304 mL | 6.6609 mL | |
| 10 mM | 0.3330 mL | 1.6652 mL | 3.3304 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
